Lam Rosanna Yen Yen. / Thesis submitted in: September 2004. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 142-154). / Abstracts in English and Chinese. / Abstract --- p.i / Chinese Abstract --- p.iii / Acknowledgements --- p.v / Table of Contents --- p.vi / List of Abbreviations --- p.xii / List of Figures --- p.xv / List of Tables --- p.xix / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Reactive oxygen species --- p.1 / Chapter 1.1.1 --- Intracellular sources of ROS --- p.1 / Chapter 1.1.2 --- Extracellular sources of ROS --- p.2 / Chapter 1.1.3 --- Superoxide anion radicals --- p.2 / Chapter 1.1.4 --- Hydrogen peroxide --- p.3 / Chapter 1.1.5 --- Hydroxyl radicals --- p.3 / Chapter 1.1.6 --- Singlet oxygen --- p.4 / Chapter 1.1.7 --- Peroxyl radicals and peroxides --- p.4 / Chapter 1.1.8 --- Damage of cellular structures by ROS --- p.5 / Chapter 1.2 --- Antioxidative defence in the body --- p.6 / Chapter 1.2.1 --- Antioxidant proteins --- p.6 / Chapter 1.2.2 --- Antioxidant enzymes --- p.6 / Chapter 1.2.3 --- Antioxidant compounds --- p.7 / Chapter 1.2.3.1 --- Vitamin E --- p.8 / Chapter 1.2.3.2 --- Vitamin C --- p.9 / Chapter 1.2.3.3 --- Glutathione --- p.9 / Chapter 1.2.3.4 --- Urate --- p.9 / Chapter 1.2.3.4.1 --- Purine metabolism --- p.10 / Chapter 1.2.3.4.2 --- Xanthine oxidase --- p.12 / Chapter 1.2.4 --- Oxidative stress and antioxidant defence mechanisms in RBC --- p.12 / Chapter 1.2.5 --- Oxidative stress and antioxidant defence mechanisms in LDL --- p.16 / Chapter 1.3 --- Human diseases originated from pro-oxidant conditions --- p.16 / Chapter 1.3.1 --- Atherosclerosis --- p.17 / Chapter 1.3.2 --- Ischemia /reperfusion injury --- p.17 / Chapter 1.3.3 --- Glucose-6-phosphate dehydrogenase deficiency --- p.18 / Chapter 1.3.4 --- DNA mutation --- p.18 / Chapter 1.3.5 --- Other pro-oxidant state related diseases --- p.19 / Chapter 1.4 --- Hyperuricemia and gout: diseases originated from an extreme antioxidant condition --- p.19 / Chapter 1.4.1 --- Inhibition of XOD as a treatment method for hyperuricemia --- p.20 / Chapter 1.4.2 --- Relationship between ROS injury and hyperuricemia --- p.22 / Chapter 1.5 --- Antioxidants in human nutrition --- p.23 / Chapter 1.6 --- Chinese medicinal therapeutics --- p.23 / Chapter 1.6.1 --- Rhubarb --- p.25 / Chapter 1.6.2 --- Aloe --- p.26 / Chapter 1.6.3 --- Ginger --- p.27 / Chapter 1.6.4 --- Objectives of the project --- p.30 / Chapter 1.6.5 --- Strategies applied to achieve the objectives of the present project --- p.30 / Chapter Chapter 2 --- Materials and methods --- p.31 / Chapter 2.1 --- XOD inhibition assay --- p.31 / Chapter 2.1.1 --- Assay development --- p.31 / Chapter 2.1.2 --- Dose-dependent study --- p.32 / Chapter 2.1.3 --- Reversibility of the enzyme inhibition --- p.32 / Chapter 2.1.4 --- Lineweaver-Burk plots --- p.33 / Chapter 2.2 --- Lipid peroxidation inhibition assay of mouse liver microsomes --- p.34 / Chapter 2.2.1 --- Preparation of mouse liver microsomes --- p.34 / Chapter 2.2.2 --- Basis of assay --- p.34 / Chapter 2.2.3 --- Assay procedures --- p.35 / Chapter 2.3 --- AAPH-induced hemolysis inhibition assay --- p.36 / Chapter 2.3.1 --- Preparation of RBC --- p.36 / Chapter 2.3.2 --- Basis of assay --- p.36 / Chapter 2.3.3 --- Assay procedures --- p.37 / Chapter 2.4 --- Lipid peroxidation inhibition assay of RBC membrane --- p.38 / Chapter 2.4.1 --- Preparation of RBC membrane --- p.38 / Chapter 2.4.2 --- Basis of assay --- p.39 / Chapter 2.4.3 --- Assay procedures --- p.40 / Chapter 2.5 --- ATPase protection assay --- p.41 / Chapter 2.5.1 --- Preparation of RBC membrane --- p.41 / Chapter 2.5.2 --- Preparation of malachite green (MG) reagent --- p.41 / Chapter 2.5.3 --- Basis of assay --- p.41 / Chapter 2.5.4 --- Assay procedures --- p.42 / Chapter 2.5.5 --- Determination of ATPase activities --- p.43 / Chapter 2.5.6 --- Assay buffers --- p.43 / Chapter 2.6 --- Sulfhydryl group protection assay --- p.44 / Chapter 2.6.1 --- Preparation of RBC membrane --- p.44 / Chapter 2.6.2 --- Basis of assay --- p.45 / Chapter 2.6.3 --- Assay procedures --- p.45 / Chapter 2.7 --- Lipid peroxidation inhibition assay of LDL by the AAPH method --- p.46 / Chapter 2.7.1 --- Basis of assay --- p.46 / Chapter 2.7.2 --- Assay procedures --- p.46 / Chapter 2.8 --- Lipid peroxidation inhibition assay of LDL by the hemin method --- p.47 / Chapter 2.8.1 --- Basis of assay --- p.47 / Chapter 2.8.2 --- Assay procedures --- p.47 / Chapter 2.9 --- Protein assay --- p.48 / Chapter 2.10 --- Statistical analysis --- p.48 / Chapter 2.11 --- Test compounds --- p.48 / Chapter Chapter 3 --- Xanthine oxidase inhibition assay: results and discussion --- p.49 / Chapter 3.1 --- Introduction --- p.49 / Chapter 3.2 --- Results --- p.54 / Chapter 3.3 --- Discussion --- p.59 / Chapter Chapter 4 --- Lipid peroxidation inhibition in mouse liver microsomes: results and discussion --- p.64 / Chapter 4.1 --- Introduction --- p.64 / Chapter 4.2 --- Results --- p.64 / Chapter 4.3 --- Discussion --- p.69 / Chapter Chapter 5 --- Assays on protection of RBC from oxidative damage: results and discussion --- p.71 / Chapter 5.1 --- Introduction --- p.71 / Chapter 5.2 --- Results --- p.75 / Chapter 5.2.1 --- AAPH-induced hemolysis inhibition assay --- p.75 / Chapter 5.2.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.82 / Chapter 5.2.3 --- Ca2+-ATPase protection assay --- p.88 / Chapter 5.2.4 --- Na+/K+-ATPase protection assay --- p.95 / Chapter 5.2.5 --- Sulfhydryl group protection assay --- p.100 / Chapter 5.3 --- Discussion --- p.110 / Chapter 5.3.1 --- AAPH-induced hemolysis inhibition assay --- p.110 / Chapter 5.3.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.111 / Chapter 5.3.3 --- Ca2+-ATPase protection assay --- p.113 / Chapter 5.3.4 --- Na+/K+-ATPase protection assay --- p.114 / Chapter 5.3.5 --- Sulfhydryl group protection assay --- p.115 / Chapter 5.3.6 --- Chapter summary --- p.117 / Chapter Chapter 6 --- Lipid peroxidation inhibition assay of LDL: results and discussion --- p.118 / Chapter 6.1 --- Introduction --- p.118 / Chapter 6.2 --- Results --- p.118 / Chapter 6.3 --- Discussion --- p.134 / Chapter Chapter 7 --- General discussion --- p.137 / References --- p.142

Made available in DSpace on 2015-07-22T20:50:37Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-03-25 / O objetivo do presente trabalho foi estimar a prevalência de hiperuricemia em nipo-brasileiros do município de Bauru (São Paulo), bem como verificar a existência de associações dessa doença com fatores nutricionais. MÉTODOS: Foram obtidos dados de 1.330 indivíduos por meio de questionários previamente testados (dados demográficos, histórico de saúde e dietéticos), exames físicos (estado de saúde e pressão arterial) e bioquímicos (ácido úrico, creatinina, glicemia de jejum e 2 horas, colesterol total e frações). Utilizaram-se o teste qui-quadrado e razões de prevalências para avaliar associação entre as variáveis nutricionais e a presença de hiperuricemia. RESULTADOS: A prevalência de hiperuricemia foi de 35,3% e acometeu, principalmente, tabagistas, indivíduos do sexo masculino, aqueles com 55 anos ou mais, com excesso de peso, obesidade central, hipertensão arterial, intolerância à glicose, hipercolesterolemia, hipertrigliceridemia, em uso de grupo específico de medicamentos e com creatinina sérica > 1,4 mg/dL. Mediante análise bruta, observaram-se relações entre hiperuricemia e o consumo de calorias totais, lipídeos, gorduras saturadas, álcool, carnes vermelhas, embutidos, leite e derivados, e frutas cítricas. Após o ajuste às variáveis de controle, permaneceram, com significância estatística, as associações entre hiperuricemia e excesso de peso, obesidade central, hipertrigliceridemia e uso de medicamentos. CONCLUSÃO: Encontrou-se elevada prevalência de hiperuricemia entre esses nipo-brasileiros, e que mudanças no perfil nutricional como redução de peso e da gordura corporal podem contribuir para minimizar a ocorrência dessa anormalidade entre esses sujeitos. / This study aimed to estimate the prevalence of hiperuricemia among Japanese-Brazilians living in Bauru city (Sao Paulo) as well to verify the existence of associations between this disease and nutritional factors. METHODS: Data were obtained from 1,330 individuals using previously tested questionnaires (demographic, health history and food intake data), physical examination (health status and blood pressure) and laboratory procedures (uric acid, creatinine, fasting and 2 h glucose, total cholesterol and fractions). Chi-square and prevalence ratios were used to evaluate associations between hyperuricemia and nutritional variables. RESULTS: The prevalence of hyperuricemia was 35.3% and it occurred more frequently among smoker individuals, men subjects, aged . 55 years, with overweight or obesity, central obesity, glucose intolerance, hypercholesterolemia, hypertrigliceridemia, using specific drugs and with creatinine levels >1.4 mg/dL. We found in the crude analysis that hiperuricemia was associated with total calories, total fat, saturated, alcohol, red and processed meats, milk and dairy products, and citric fruits intake. After control variables adjustment remained statistically significant the associations between hyperuricemia and body weight excess, central obesity, hypertrigliceridemia and use of specific drugs. CONCLUSION: High hiperuricemia prevalence rate was found among these Japanese-Brazilians and changes in nutritional profile including weight and body fat reductions may help to minimize the occurrence of this disease in that community. / TEDE / BV UNIFESP: Teses e dissertações

Submitted by Geandra Rodrigues (geandrar@gmail.com) on 2018-04-27T11:55:53Z No. of bitstreams: 1 analuisasilveiravieiratollendal.pdf: 1031624 bytes, checksum: 2a4a0647b9d22be1da3f719765d6d470 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2018-04-27T12:09:21Z (GMT) No. of bitstreams: 1 analuisasilveiravieiratollendal.pdf: 1031624 bytes, checksum: 2a4a0647b9d22be1da3f719765d6d470 (MD5) / Made available in DSpace on 2018-04-27T12:09:21Z (GMT). No. of bitstreams: 1 analuisasilveiravieiratollendal.pdf: 1031624 bytes, checksum: 2a4a0647b9d22be1da3f719765d6d470 (MD5) Previous issue date: 2018-01-19 / Introdução: A doença renal crônica (DRC) se tornou uma preocupante questão de saúde pública em todo o mundo devido às suas crescentes incidência e prevalência e ao impacto em morbimortalidade por ela desencadeado. O tratamento da DRC se baseia na intervenção em seus fatores de risco. Entretanto, os fatores atualmente conhecidos e sua abordagem não têm sido suficientes para conter a doença. Por esse motivo, torna-se imprescindível a busca por outros fatores associados à sua patogênese. Nesse sentido, a hiperuricemia tem sido apontada, nas últimas décadas, como uma condição associada à DRC, porém sem que ainda tenha sido estabelecida uma associação causal entre ambas. Objetivos: 1. Avaliar as evidências sobre o impacto da hiperuricemia na incidência e progressão da DRC, através de revisão sistemática da literatura; 2. Avaliar o impacto dos níveis séricos de ácido úrico (AU) sobre o declínio da taxa de filtração glomerular (TFG) em uma população de pacientes com DRC. Métodos: Primeiramente, realizou-se revisão sistemática da literatura com busca por artigos publicados no período entre Janeiro de 2005 e Dezembro de 2016, utilizando-se a combinação de palavraschave “chronic renal insufficiency AND hyperuricemia AND uric acid” nos bancos de dados Lilacs e Pubmed. Os resumos dos artigos foram avaliados por dois pesquisadores, de acordo com os critérios de inclusão e exclusão estabelecidos. Na segunda fase do estudo, 788 pacientes incidentes no ambulatório de DRC do Centro Hiperdia Minas/Juiz de Fora tiveram seus registros eletrônicos analisados e o impacto dos níveis de AU na progressão da DRC foi avaliado. Resultados: Relativamente à revisão sistemática, foram encontrados 150 estudos envolvendo seres humanos, dos quais 22 foram elegíveis, 13 estudos avaliaram incidência e 11 avaliaram progressão da DRC (aumento de creatinina, variação da taxa de filtração glomerular, início de terapia renal substitutiva); dois avaliaram ambos os desfechos. Todos os treze artigos que avaliaram associação entre hiperuricemia e incidência de DRC mostraram associação positiva entre ambas. Uma metanálise avaliou impacto da hiperuricemia em 190.718 indivíduos e encontrou relação causal independente para incidência de DRC. Em relação à progressão da DRC, os estudos longitudinais apresentaram resultados conflitantes e três estudos randomizados controlados foram identificados, comparando um grupo tratado com alopurinol e um grupo controle, todos com melhora dos desfechos renais no grupo tratado. Os resultados da análise do banco de dados do Centro HIPERDIA mostraram que pacientes admitidos com hiperuricemia, ou seja, AU maior do que 6,8mg/dL, apresentaram risco quase duas vezes maior (IRR=1,91 95% IC: 1,21-3,00, p=0,005) de progressão rápida da DRC (TFG>5mL/min/ano). Além disso, para cada 1 mg/dL de aumento nos níveis basais de AU houve risco anual 48% maior de progressão rápida (IRR=1,48 95% IC:1,16-1,88, p=0,001). Conclusão: A revisão sistemática sugeriu que hiperuricemia se associa de forma independente com incidência de DRC, porém seu papel na progressão da doença ainda é controverso. Entre os pacientes com DRC do Centro Hiperdia Minas/Juiz de Fora, os níveis séricos aumentados de AU associaramse a maior risco de progressão rápida da doença renal crônica. / Introduction: Chronic kidney disease (CKD) has become a worrisome public health problem worldwide due to its increasing incidence and prevalence as well as its impact on morbidity and mortality. Treatment of CKD is based on risk factor intervention. However, currently known factors and their approach are insufficient to stop the disease. For this reason, it is imperative to search for other factors associated with its pathogenesis. Hyperuricemia has been identified as a condition associated with CKD, but causal association between them has not yet been proved. Objectives: 1. To evaluate the impact of hyperuricemia on the incidence and progression of CKD through a systematic review of the literature; 2. To evaluate the impact of serum uric acid levels on the decline of the glomerular filtration rate (GFR) in a population of chronic renal patients. Methods: Initially a systematic review of the literature was carried out between January 2005 and December 2016. The combination of keywords "chronic renal insufficiency AND hyperuricemia AND uric acid" was used to search in the Lilacs and Pubmed databases. The articles’ abstracts were evaluated by two researchers according to established inclusion and exclusion criteria. Secondly, the electronic records of 788 patients of the CKD outpatient clinic of the Hiperdia Minas/Juiz de Fora Center were analyzed and the impact of uric acid levels on the progression of CKD was evaluated. Results: A total of 150 studies involving humans were found. Twenty two were eligible; 13 studies evaluated incidence and 11 evaluated progression of CKD (increase in creatinine, variation of glomerular filtration rate, initiation of renal replacement therapy); two of the articles evaluated both outcomes. All thirteen articles that assessed the association between hyperuricemia and incidence of CKD showed a positive association between both. A further meta-analysis of 190,718 individuals evaluated the impact of hyperuricemia on the incidence of CKD and found an independent causal relationship. Regarding the progression of CKD, longitudinal studies presented conflicting results; three randomized controlled trials compared a group treated with allopurinol and a control group, all with improvement of the renal outcomes within the treated group. The Hiperdia Center database analysis results showed that patients admitted with hyperuricemia, that is, uric acid higher than 6.8mg/dL, presented almost twice the risk (IRR = 1.91 95% CI: 1, 21-3.00, p = 0.005) of rapid progression of CKD (TFG> 5mL/min/year). In addition, for each 1 mg/dL increase in the uric acid levels baseline, there was an additional 48% annual risk of progression (IRR = 1.48 95% CI: 1.16-1.88, p = 0.001). Conclusion: The systematic review suggested that hyperuricemia is independently related to the incidence of CKD, however, its role in disease progression is still controversial. Among patients with CKD, increased serum uric acid levels were associated with an increased progression of chronic kidney disease.

Submitted by Fabio Sobreira Campos da Costa (fabio.sobreira@ufpe.br) on 2016-04-18T13:17:39Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Tese Tiago Araújo.compressed.pdf: 7089899 bytes, checksum: 0d9fa1d7f42954a36ff78b4171da7ef7 (MD5) / Made available in DSpace on 2016-04-18T13:17:39Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Tese Tiago Araújo.compressed.pdf: 7089899 bytes, checksum: 0d9fa1d7f42954a36ff78b4171da7ef7 (MD5) Previous issue date: 2015-04-30 / CAPEs / O presente estudo teve como objetivo investigar a relação entre hiperuricemia, distúrbios metabólicos e as atividades biológicas de Myrciaria cauliflora, Crataeva tapia e Indigofera suffruticosa. Para tanto, foi realizado inicialmente um estudo populacional, com 3620 voluntários, adultos, homens, não diabéticos, do Nordeste brasileiro. Obesidade abdominal e hipertrigliceridemia foram avaliadas para a identificação do fenótipo denominado Cintura Hipertrigliceridêmica (CHTG) e para a avaliação da influência desses distúrbios metabólicos sobre a hiperuricemia. Posteriormente, estudos com modelo animal (Mus musculus) foram conduzidos. Assim, extratos orgânicos (etéreo, acetônico e metanólico) foram preparados a partir do epicarpo de frutos maduros de M. cauliflora, denominados, sequencialmente, de MCEE, MCAE e MCME, nas concentrações de 200mg/Kg e de 400mg/Kg. Análise fitoquímica e estudo da toxicidade oral desses extratos foram realizadas. MCAE foi administrado durante 14 dias em camundongos com diabetes induzida por aloxana; e avaliação do perfil glicídico, lipídico, de função renal e hepática e análise histológica do pâncreas foram realizadas. Atividade anti-hiperuricêmica de MCAE, em modelo de oxonato de potássio, também foi investigada. MCEE, MCAE e MCME foram usados para a avaliação de: atividade anti-inflamatória, usando os modelos de edema de pata e de peritonite; atividade antinociceptiva, nos modelos de dor induzida por ácido acético e de placa quente; atividade antioxidante, por ensaio com 2,2-difenil-β- picrilhidrazil; e atividade antitumoral, contra tumor sólido de carcinoma de Ehrlich. Lectina de C. tapia foi purificada e testada para avaliação de atividade hipoglicêmica. Extratos etéreo, clorofórmico e acetônico de folhas de I. suffruticosa foram preparados, analisados fitoquimicamente e testados contra cepas de S. aureus. Como principais resultados, este estudo demonstrou que: obesidade abdominal e hipertrigliceridemia, isoladas, mostraram significativas razões de chance (RC) sobre a presença de hiperuricemia, porem o fenótipo CHTG demonstrou o maior efeito (RC = 4,3), especialmente após o uso dos pontos de corte obtidos especificamente para a população do estudo; hiperuricemia apresentou uma forte associação com alto risco de morte por evento cardiovascular em dez anos (RC = 3,5); 200mg/Kg/dia e 400mg/Kg/dia de MCAE causou uma redução significativa da glicose plasmática e redução nos níveis séricos de triglicerídios, uréia, creatinina e transaminases, aumento de HDL-colesterol, melhora do aspecto morfológico das ilhotas pancreáticas e diminuição de cerca de 50% nos níveis de ácido úrico; MCEE, MCAE e MCME apresentaram relevante atividade antioxidante e produziram reduções significativas da resposta inflamatória, de nocicepção e da massa tumoral; lectina de C. tapia provocou redução significativa nos níveis de glicose, melhora das funções e dos aspectos morfológicos dos rins, pâncreas e fígado de camundongos diabéticos; o extrato acetônico de folhas de I. suffruticosa foi um potente inibidor de S. aureus, seguido pelo extrato clorofórmico, melhorando também sinergisticamente o efeito da eritromicina. Portanto, hiperuricemia está bastante relacionada com o fenótipo CHTG em homens do Nordeste do Brasil, podendo elevar em muito o risco cardiovascular desses indivíduos. M. cauliflora demonstrou um grande potencial terapêutico para hiperuricemia e as condições metabólicas associadas e, assim como lectina de C. tapia, demonstrou ser um agente promissor para o tratamento da diabetes; enquanto que I. suffruticosa mostrou-se ser bastante promissora contra S. aureus. / This study aimed to investigate the relationship among hyperuricemia, metabolic disorders and the biological activities of Myrciaria cauliflora, Crataeva tapia e Indigofera suffruticosa. Therefore, it was initially performed a population study, with 3620 volunteers, adults, men, non-diabetic, from northeastern Brazil. Abdominal obesity and hypertriglyceridemia were evaluated for the identification of phenotype referred as Hypertriglyceridemic Waist (HTGW) and to assess the influence of these metabolic disorders hyperuricemia. Later, animal model studies (Mus musculus) were conducted. Thus, organic extracts (ether, acetone, and methanol) were prepared from ripe fruit epicarp of M. cauliflora referred to, sequentially, MCEE, MCAE, and MCME, at concentrations of 200mg/Kg and 400mg/Kg. Phytochemical analysis and study of oral toxicity of these extracts were made. MCAE was administered for 14 days in mice with alloxan-induced diabetes; and evaluation of glucose profile, lipid, renal and hepatic function and histological analysis of the pancreas were performed. Anti-hyperuricemic activity of MCAE, in potassium oxonate model, was investigated. MCEE, MCAE, and MCME were used for evaluation of: anti-inflammatory activity, using the rat paw edema model and peritonitis; antinociceptive activity, in models of pain induced by acetic acid and hot plate; antioxidant activity, by 2,2-diphenyl-β-picrylhydrazyl assay; and antitumor activity against solid tumor of Ehrlich carcinoma. Lectin of C. tapia was purified and tested for evaluation of hypoglycemic activity. Ether, chloroform and acetone extracts of leaves of I. suffruticosa were prepared, phytochemically analyzed and tested against strains of S. aureus. As main results, this study demonstrated that: abdominal obesity and hypertriglyceridemia, isolated, showed significant odds ratios (OR) for the presence of hyperuricemia, but HTGW phenotype demonstrated the most effect (OR = 4.3), especially after use the cutoffs obtained specifically for the study population; hyperuricemia showed a strong association with high risk of cardiovascular events death in ten years (OR = 3.5); 200mg/Kg/dia and 400mg/Kg/dia of MCAE caused a significant reduction in plasma glucose and reduction in serum levels of triglycerides, urea, creatinine and transaminases, increase in HDL-cholesterol, improvement in the morphological appearance of the pancreatic islets and decrease about 50% in the levels of uric acid; MCEE, MCAE, and MCME presented significant antioxidant activity and produced significant reductions in the inflammatory response, nociception and of the tumor mass; C. tapia lectin caused a significant reduction in glucose levels, improved the function and morphology of the kidneys, pancreas and liver of diabetic mice; and the acetone extract from the leaves of I. suffruticosa was a potent inhibitor of S. aureus followed by chloroform extract, also synergistically improving the effect of erythromycin. Therefore, hyperuricemia is closely related to the HTGW phenotype in men in Northeast Brazil, and can significantly increase the cardiovascular risk of these individuals. M. cauliflora demonstrated a great therapeutic potential for hyperuricemia and associated metabolic conditions, as well as C. tapia lectin proved to be a promising agent for the treatment of diabetes; while I. suffruticosa shown to be quite promising against S. aureus.

Uric acid excretion disorders are the most common cause of primary dysuricemia. The kidneys eliminate two-thirds of uric acid production and the other third is eliminated in the gastrointestinal tract. Renal reabsorption and secretion occur through the polarised epithelial cells in the proximal tubules. Uric acid transporters are expressed on these cell membranes. Reabsorption deficiency leads to hypouricemia and elevated fraction excretion associated with urolithiasis, nephrolithiasis or acute renal injury. Decreased uric acid secretion in the kidneys and small intestine leads to hyperuricemia, which develops into gout in 10% of individuals. Genome wide association studies detected a strong effect of SLC22A12 (URAT1), SLC2A9 (GLUT9) reabsorbing transporters and ABCG2 (ABCG2) secreting transporter on uric acid serum concentration variability. This thesis aimed to map out urate transporter allelic variants in a cohort of primary dysuricemia patients and identification of the variants causing defective uric acid excretion. Six non-synonymous variants were described in SLC22A12 (URAT1) and SLC2A9 (GLUT9) genes in hypouricemic individuals, which had not been identified previously in any population studies. Significant decreases in uric acid transport have been demonstrated experimentally in vitro,...

Uric acid excretion disorders are the most common cause of primary dysuricemia. The kidneys eliminate two-thirds of uric acid production and the other third is eliminated in the gastrointestinal tract. Renal reabsorption and secretion occur through the polarised epithelial cells in the proximal tubules. Uric acid transporters are expressed on these cell membranes. Reabsorption deficiency leads to hypouricemia and elevated fraction excretion associated with urolithiasis, nephrolithiasis or acute renal injury. Decreased uric acid secretion in the kidneys and small intestine leads to hyperuricemia, which develops into gout in 10% of individuals. Genome wide association studies detected a strong effect of SLC22A12 (URAT1), SLC2A9 (GLUT9) reabsorbing transporters and ABCG2 (ABCG2) secreting transporter on uric acid serum concentration variability. This thesis aimed to map out urate transporter allelic variants in a cohort of primary dysuricemia patients and identification of the variants causing defective uric acid excretion. Six non-synonymous variants were described in SLC22A12 (URAT1) and SLC2A9 (GLUT9) genes in hypouricemic individuals, which had not been identified previously in any population studies. Significant decreases in uric acid transport have been demonstrated experimentally in vitro,...

No description available.

Febuxostat is a novel non purine drug indicated for the treatment of hyperuricemia in gout. A reversed-phase liquid chromatography (RP-LC) method was validated for the determination of febuxostat in pharmaceutical dosage forms. The LC method was carried out on a XTerra C18 column (150 mm x 3.9 mm I.D.), maintained at 25 ºC. The mobile phase consisted of water (pH 3.5) acetonitrile (40:60, v/v), run at a flow rate of 0.8 mL/min and using photodiode array (PDA) detection at 316 nm. The chromatographic separation was obtained with retention time of 3.9 min, and was linear over the range of 0.25 - 30 μg/mL (r2=0.9995). The specificity and stability-indicating capability of the method was proven through degradation studies were carried out by LC and MS and showing also, that there was no interference of the excipients and degradation products in the quantification of the drug. Moreover, the in vitro cytotoxicity test of the degraded products showed significant differences (p<0.05). The accuracy was 100.54% with bias lower than 0.65%. The limits of detection and quantitation were 0.08 and 0.28 μg/mL, respectively. The procedure was validated evaluating parameters such as the specificity, linearity, precision, accuracy, limits of detection and quantitation, robustness, and system suitability test, giving results within the acceptable range. The proposed method was applied for dissolution studies and the analysis of tablet dosage forms, contributing to assure the safety and therapeutic efficacy. / Febuxostate é um novo fármaco, não purínico, indicado para o tratamento da hiperuricemia em pacientes com gota. No presente trabalho foi desenvolvido e validado método por cromatografia líquida em fase reversa (CL-FR) para determinação de febuxostate em produtos farmacêuticos. No método por CL-FR foi utilizada coluna XTerra C18 (150 mm x 3,9 mm d.i), mantida a 25 oC. A fase móvel foi composta de água ultra-pura (pH 3,5): acetonitrila (40:60, v/v), eluída na vazão de 0,8 mL/ min com detecção no ultravioleta a 316 nm. A separação cromatográfica foi obtida no tempo de 3,9 min, sendo linear na faixa de concentração de 0,25-30 μg/mL (r2=0,9995). A especificidade do método foi comprovada através de estudos de degradação realizados por cromatografia líquida e espectrometria de massas, demonstrando que não houve interferência dos excipientes e dos produtos de degradação na quantificação do fármaco. Além disso, o teste de citotoxicidade in vitro das amostras degradadas, apresentou diferenças significativas (p <0,05) em relação à forma intacta. A precisão foi de 100,54%, com bias menor do que 0,65%. Os limites de detecção e de quantificação foram de 0,08 e 0,28 μg/mL, respectivamente. O procedimento foi validado, avaliando-se os parâmetros de especificidade, linearidade, precisão, exatidão, limite de detecção e quantificação, robustez e teste de adequabilidade do sistema, cujos resultados estão de acordo com os requisitos preconizados. O método proposto foi aplicado no estudo de dissolução e análise de formas farmacêuticas de comprimidos, contribuindo, assim, para aprimorar o controle da qualidade de medicamentos, bem como garantir a segurança e eficácia no uso terapêutico.

Objetivo: Evaluar la asociación entre Obesidad Abdominal (OA) e Hiperuricemia (HU) en adultos diagnosticados con diabetes mellitus tipo 2 (DM2). Métodos: Estudio analítico de tipo transversal, en adultos con DM2 que acudieron a una Clínica Privada de Lima - Perú durante el 2018. Se consideró HU a valores séricos de ácido úrico mayores o iguales a 6 mg/dL y para definir OA se utilizó el perímetro de cintura mayor o igual a 94 cm y 88 cm en hombres y mujeres, respectivamente. Se utilizaron razones de prevalencia (RP) crudas y ajustadas con sus intervalos de confianza al Resultados: Se evaluó a 737 adultos con DM2. El 61,7 % fueron varones y la edad promedio fue 57 años. El 83,2 % presentó OA y el 21,7% HU. La prevalencia de HU en los adultos con OA fue de 23,1% mientras que la prevalencia fue de 14,5 % para los que no eran obesos. La OA se asoció con la HU en el análisis crudo (RP: 1,59 IC95% 1,01-2,50) y se mantuvo estadísticamente significativa en el análisis ajustado (RP: 1,59 IC95% 1,04-2,41) Conclusión: Los participantes diabéticos con OA tienen casi el doble de probabilidad de presentar HU en comparación con los diabéticos sin OA. / Objective: To evaluate the association between Abdominal Obesity (AO) and Hyperuricemia (HU) in adults diagnosed with type 2 diabetes mellitus (TDM2). Methods: Cross-sectional observational study in adults with TDM2 in a private clinic in Lima - Peru. We define HU as serum uric acid values greater than or equal to 6 mg/dL and AO as a waist circumference greater than or equal to 94 cm and 88 cm in men and women, respectively. Crude and adjusted prevalence ratios (PR) were used by 95% confidence intervals. Results: 737 adults with TDM2 were evaluated. 61.7% were male, and the average age was 57 years. AO was present in 83.2 % and HU in 21.7%. The prevalence of HU in adults with AO was 23.1%, while the prevalence was 14.5 % in those not obese. AO was associated with HU in the crude analysis (PR: 1.59 95% CI 1.01-2.50) and remained statistically significant in the adjusted analysis (PR: 1.59 95% CI 1.04-2.41) Conclusion: Diabetic participants with AO are almost twice likely to have HU compared to patients with TDM2 without AO. / Tesis